| Esophageal cancer is one of the most common malignant diseases in our country. Although the different available therapies, which including surgical operation, radical therapy, and chemical therapy, have currently been used in the treatment of esophageal cancer, and all of these have markedly improved the prognosis of esophageal cancer. But the results are not satisfied. Clinically, most of esophageal cancer patients are in middle or late stage. For metastasis and recurrence after operation, the 5 year survival rate is always poor.Tumor invasion and metastasis have to break down the barriers of extra cellular matrix (ECM) and blood vessel basement membranes (BM). Heparan sulphate proteoglycans (HSPGs) is one of the main components of ECM and BM. Heparanase (Hpa) is a kind of endo-β-glucuronidases, which is the only found to degrade HSPGs. It can cleaves heparin sulfate(HS) to degrade ECM and BM, and can facilitate to release or activate the HSPG-bounded growth factors(such as bFGF, VEGF et al.) to induce angiogenesis. In this way, Hpa promotes tumor invasion and metastasis. It is becoming a new target to treat cancer with the development of the study about the relationship between the Hpa and the tumor invasion and metastasis.This study contains five parts of work to research the relation between Hpa and esophageal squamous cell cancer: 1.The relationships between the expression of Hpa and ESCC clinic-pathological features; 2.The expression of Hpa in normal esophageal epithelia, precancerous lesions and squamous cell cancer; 3. Synthesized heparanase antisense oligodeoxynucleotide (Hpa ASODN)is transferred in TE-13 cell line by liposome to explore the effect of silencing Hpa gene and protein and the effect of inhibiting cell invasive ability; 4. Hpa inhibitor PI-88 is used to explore its effect of TE-13 cell proliferation, Hpa gene and protein expression; PI-88 and Hpa ASODN are administrated combinedly to observe the effect to TE-13 cell invasive ability; 5.PI-88 and...
|
PDF Full Text Request